Impact of an Antibiotic (Rifaximin) on Liver Scarring in HIV-Infected Patients With Liver Disease

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2012 by Icahn School of Medicine at Mount Sinai.
Recruitment status was  Recruiting
Salix Pharmaceuticals
Information provided by (Responsible Party):
Douglas T. Dieterich, Mount Sinai School of Medicine Identifier:
First received: July 30, 2012
Last updated: October 24, 2012
Last verified: October 2012
No Study Results Posted on for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: September 2013
  Estimated Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)